Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate.
Patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, but the outcome remains unsatisfactory for patients with relapsed disease, including those patients with refractory disease after bone marrow transplantation. Targeted therapies have changed the standard of care for many advanced solid tumors. We have identified, in the literature, potential targets for the treatment of refractory germ cell tumors, and applied to a patient with a refractory disease. We chose sunitinib for this purpose. To our knowledge, this is the first case to be treated with sunitinib, and we have found a promising activity.
Gasent Blesa
Joan Manel
JM
Hospital de Dénia, Marina Salud, Dénia, Valencia, Spain.
Grande Pulido
Enrique
E
Laforga Canales
Juan
J
Alberola Candel
Vicente
V